|
December 14, 2011
CLINICAL NEUROSCIENTIST, WILLIAM Z. POTTER, M.D., PH.D., JOINS ENVOY'S ADVISORY BOARD
December 7, 2011
PEARL THERAPEUTICS REPORTS POSITIVE PHASE 2B RESULTS OF PT001 IN PATIENTS WITH COPD
December 5, 2011
DVS SCIENCES APPOINTS JOSEPH VICTOR AS PRESIDENT AND CEO
October 11, 2011
CLEAVE BIOSCIENCES RAISES $42 MILLION IN SERIES A FINANCING FOR NOVEL CANCER THERAPIES
October 10, 2011
INCLINE ADVANCES PAIN MED, SECURES SECOND TRANCHE OF $50M FINANCING
September 28, 2011
ACHAOGEN APPOINTS CHIEF MEDICAL OFFICER KENNETH HILLAN TO CHIEF EXECUTIVE OFFICER
September 26, 2011
PEARL THERAPEUTICS' BRONCHODILATOR COMBINATION PT003 PROVIDES SUPERIOR INSPIRATORY CAPACITY COMPARED TO SPIRIVAŽ
September 22, 2011
BRISTOL-MYERS SQUIBB AND AMBRX ANNOUNCE COLLABORATION FOR NOVEL BIOLOGICS PROGRAMS IN DIABETES AND HEART FAILURE
September 6, 2011
FIERCEBIOTECH NAMES PEARL THERAPEUTICS A 2011 FIERCE 15 BIOTECH
August 31, 2011
ENVOY GARNERS FLORIDA GOVERNOR'S 2011 BUSINESS DIVERSIFICATION AWARD
August 30, 2011
PEARL THERAPEUTICS ANNOUNCES POSITIVE RESULTS FOR PHASE 2B DOSE-RANGING STUDY OF FORMOTEROL MDI
August 15, 2011
PULMATRIX SECURES A $14 MILLION FINANCING TO ADVANCE CLINICAL PROGRAMS IN COPD AND CYSTIC FIBROSIS
August 5, 2011
BIOTIE THERAPIES CORP. INTERIM REPORT 1 JANUARY - 30 JUNE 2011
July 25, 2011
BIOTIE ADVANCES CLINICAL PROGRAM FOR SYN120 WITH IMAGING STUDY AT JOHNS HOPKINS CENTER OF EXCELLENCE
July 14, 2011
DVS SCIENCES RAISES $14.6 MILLION IN SERIES A FINANCING TO ADVANCE COMMERCIALIZATION OF NOVEL SINGLE-CELL ANALYSIS TECHNOLOGY
July 11, 2011
VIVEVE SPONSORS STUDY IN JAPAN FOR NEW PROCEDURE TO TREAT VAGINAL LAXITY
June 28, 2011
RELYPSA BEGINS TREATMENT IN AMETHYST-DN TRIAL OF RLY5016 FOR HYPERKALEMIA IN DIABETIC NEPHROPATHY PATIENTS WITH CHRONIC KIDNEY DISEASE
June 20, 2011
ANAPHORE APPOINTS PAUL A. GRAYSON PRESIDENT AND CEO
June 16, 2011
PEARL THERAPEUTICS ADVANCES ITS LONG-ACTING BRONCHODILATOR COMBINATION PRODUCT CANDIDATE INTO FOUR ADDITIONAL PHASE 2 STUDIES
May 18, 2011
PEARL THERAPEUTICS' PHASE 2B RESULTS SHOW A 50% IMPROVEMENT IN LUNG FUNCTION WITH PT003 COMPARED TO SPIRIVA® AND FORADIL® IN PATIENTS WITH COPD
May 5, 2011
PEARL THERAPEUTICS HIGHLIGHTS ITS POROUS PARTICLE COSUSPENSION PLATFORM, DEMONSTRATING UNIVERSAL APPLICABILITY ACROSS MULTIPLE DRUG CLASSES AND COMBINATION PRODUCTS
April 29, 2011
PEARL THERAPEUTICS TO PRESENT COMPLETE PT003 RESULTS FROM PHASE 2B COPD STUDY IN A LATE-BREAKER SESSION AT THE AMERICAN THORACIC SOCIETY ANNUAL MEETING
April 7, 2011
BIOTIE ANNOUNCES START OF PHASE 2B TRIAL OF SYN115 IN PARKINSON'S DISEASE
March 24, 2011
VBI PROGRESSING WITH VACCINES THAT DON'T REQUIRE REFRIGERATION
March 23, 2011
KALOBIOS INITIATES PHASE 1 CLINICAL TRIAL OF KB004 IN EPHA3-EXPRESSING HEMATOLOGIC MALIGNANCIES
March 14, 2011
WILDCAT DISCOVERY TECHNOLOGIES DISCLOSES FUNDAMENTAL ADVANCES IN RECHARGEABLE BATTERY MATERIALS TECHNOLOGY
February 2, 2011
MARCADIA MAY FETCH UP TO $537 MILLION IN SALE
February 2, 2011
THE ACQUISITION OF SYNOSIA THERAPEUTICS HOLDING AG COMPLETED
January 10, 2011
BIOTIE AND SYNOSIA TO COMBINE TO CREATE A LEADING CNS DEVELOPMENT COMPANY
|
